source
- Patient finds open-source diabetes app improves control despite lack of FDA approvalPatient has type 1 diabetes for over 30 years and has used FDA-approved pumps and sensors that were upgraded roughly every five years. Over time his glucose control slipped despite the regulated de…
- Novo vs. Lilly: Q2's cardiometabolic grudge matchFor years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of c…